antiviral compounds (Vivalis)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug Nameantiviral compounds (Vivalis)

Drug Alias Nameprotease- and polymerase-targeting small-molecules (Vivalis)VVS-2VVS-1VVS-3

ClassificationSmall molecules

Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsHepatitis C virus replication inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitors

TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseHepatitis C virus serine protease, NS3/NS4A

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesValneva SE

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesValneva SE

Active IndicationsN/A

Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A